Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Schizophrenia: symptoms
3. Schizophrenia: the therapeutic challenge
4. Hypothesized DA/5-HT pathways in schizophrenia
5. DA and 5-HT: hypothesis of schizophrenia
6. DA pathways for movement in basal ganglia
7. Other ADRs to antipsychotics: elevated prolactin
8. Variation in response and ADRs
9. Psychiatric pharmacogenetics: definition
10. Biological-environmental-demographic interactions
11. Complex trait genetics
12. Our clinical sample
13. Genetic association strategy
14. Tardive dyskinesia (TD): pharmacogenetic studies
15. TD: symptoms
16. TD: oro-facial symptoms
17. TD and tardive dystonia: truncal symptoms
18. TD: postulated pathophysiology
19. TD: genetic rationale
20. Hypothesis: variation and susceptibility to TD
21. Pharmacodynamic candidates: DRD3 gene
22. Neuroanatomical distributions of DA receptors
23. Why DRD3?
24. DRD3 variation
25. DRD3 Msc I polymorphism: mean AIMS scores
26. Stratified analysis
27. Brain metabolism and DRD3 genotype: FDG-PET
28. TD and DRD3 gene: references (1)
29. TD and DRD3 gene: references (2)
30. TD and DRD3 gene: meta-analysis
31. Pharmacodynamic candidates: 5-HTR2A gene
32. DRD and 5-HTR genes: hypotheses of TD
33. Dopaminergic and serotonergic interactions
34. Antipsychotics and receptor binding profile
35. Atypical antipsychotics: fast-on fast-off theory (1)
36. Atypical antipsychotics: fast-on fast-off theory (2)
37. Theories of "atypical" antipsychotic action
38. HTR2A polymorphisms
39. HTR2A polymorphism: mean AIMS scores
40. TD and HTR2A gene: references
41. TD and other HTR genes: references
42. TD and HTR2A gene: meta-analysis

Topics Covered

• Postulated mechanisms of schizophrenia
• Dopaminergic pathways in schizophrenia
• The Pharmacogenetic paradigm
• Pharmacokinetic-pharmacodynamic-environmental interactions
• Complex trait genetics
• Antipsychotic adverse reactions
• Tardive dyskinesia
• Postulated mechanisms
• Genetic association studies of TD
• Candidate genes in TD
• Pharmacodynamics and TD: a look at dopaminergic and serotonergic candidates

Links

Series:

• Psychopharmacogenetics

Categories:

• Genetics & Epigenetics
• Neuroscience
• Pharmaceutical Sciences

Therapeutic Areas:

• Neurology

Talk Citation

Basile, V. (2007, October 1). Pharmacogenetics of tardive dyskinesia: a "movement" towards individualized therapy 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/AGNC2901.
Export Citation (RIS)

Publication History

• Published on October 1, 2007
• Archived on February 25, 2021

Financial Disclosures

• Dr. Vincenzo Basile has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.